Blog
RSS FeedPosted by Michael Wonder on 29 Aug 2023
Australia knocks back application for diabetes drug that could overshadow Ozempic
29 August 2023 - Australia has knocked back an application to subsidise the diabetes drug Mounjaro but the manufacturer still wants ...
Posted by Michael Wonder on 21 Aug 2023
Recommendations made by the PBAC (July 2023)
18 August 2023 - Recommendations made by the PBAC in July 2023 relating to the listing of medicines on the ...
Posted by Michael Wonder on 18 Aug 2023
Estimating overall survival in people receiving PBS listed cancer medicines in Australian clinical practice
18 August 2023 - In September 2021, the Department of Health and Aged Care contracted the Medicines Intelligence Centre for ...
Posted by Michael Wonder on 18 Jul 2023
Outcome statement - June 2023 DUSC meeting
18 July 2023 - The outcome statement from the June 2023 DUSC meeting is now available. ...
Posted by Michael Wonder on 23 Jun 2023
Changes to PBS eligibility criteria for Paxlovid
23 June 2023 - In an out of session consideration, the PBAC has recommended changes to the circumstances under which nirmatrelvir ...
Posted by Michael Wonder on 16 Jun 2023
Outcomes of the May 2023 PBAC intracycle meeting
16 June 2023 - The outcomes from the May 2023 PBAC intracycle meeting are now available. ...
Posted by Michael Wonder on 24 May 2023
Revolutionising MS treatment: new form of Tysabri recommended for PBS listing
24 May 2023 - The PBAC has recommended the listing of natalizumab (Tysabri) pre-filled syringe for subcutaneous injection on the PBS. ...
Posted by Michael Wonder on 12 May 2023
Outcome in relation to fluticasone propionate – May 2023 PBAC intracycle meeting
12 May 2023 - The outcome for fluticasone propionate from the May 2023 PBAC meeting is now available. ...
Posted by Michael Wonder on 10 May 2023
Recommendations made out-of-session by the PBAC between March 2023 and July 2023 meetings
10 May 2023 - Recommendations made out-of-session by the PBAC between its March 2023 and July 2023 meetings are now available. ...
Posted by Michael Wonder on 21 Apr 2023
Recommendations made by the PBAC (March 2023)
21 April 2023 - Recommendations made by the PBAC in March 2023 relating to the listing of medicines on the Pharmaceutical ...
Posted by Michael Wonder on 01 Apr 2023
Outcome statement - February 2023 DUSC meeting
31 March 2023 - The outcome statement from the February 2023 DUSC meeting is now available. ...
Posted by Michael Wonder on 24 Feb 2023
Recommendations made out of session by the PBAC November 2022 and March 2023 meetings
24 February 2023 - Recommendations made out of session by the PBAC between its November 2022 and March 2023 meetings are ...
Posted by Michael Wonder on 27 Jan 2023
Recommendations made by the PBAC – December 2022 intracycle meeting
27 January 2023 - Recommendations made by the PBAC in December 2022 relating to the listing of drugs on the PBS ...
Posted by Michael Wonder on 22 Dec 2022
Final report for the post-market review of medicines for smoking cessation and review outcomes
22 December 2022 - The final report for the post-market review of medicines for smoking cessation is now available. The ...
Posted by Michael Wonder on 16 Dec 2022
Recommendations made by the PBAC – November 2022
16 December 2022 - The outcomes from the November 2022 PBAC meeting are now available. ...